At our institution, High Dose Rate Brachytherapy has been used since 1998 as a pre-operative radiation modality and more than 1200 patients have been treated with very favorable oncological outcomes when compared to matched pair control (Breugom et al. 2015).
This modality is offered to patients with stage II and early stage III (N1) rectal cancer as an option to standard chemotherapy and external beam vs. short course pelvic radiation therapy.
It is a solution for patients who had received previous pelvis radiation and needs tumour downstaging prior to surgery.
This study explores the use of a novel rectal applicator approved by Health Canada which could considerably reduce the treatment time and provide a more comfortable experience for patients.
This study is exploring two non-operative treatment strategies using dose escalation either with external beam radiation or targeted endorectal brachytherapy.
This pilot study seeks to provide information to patients regarding present available treatment options and their related side effects
The purpose of this study is to evaluate the degree of low anterior resection syndrome manifested in patients with cancer treated in the pelvic area and that were treated with surgery alone.